Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 5
2001 2
2002 5
2003 6
2004 9
2005 5
2006 5
2007 6
2008 4
2009 4
2010 5
2011 6
2012 2
2014 3
2016 3
2017 3
2018 3
2019 3
2020 3
2021 1
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: wacheck v. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. DiPeri TP, et al. Among authors: wacheck v. J Hepatol. 2024 Feb;80(2):322-334. doi: 10.1016/j.jhep.2023.10.041. Epub 2023 Nov 14. J Hepatol. 2024. PMID: 37972659
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, McKnight C, Itkin Z, Sotome H, Hirai H, Calleja E, Wacheck V, Gouker B, Peer CJ, Corvalan N, Milewski D, Kim YY, Figg WD, Edmondson EF, Thomas CJ, Difilippantonio S, Wei JS, Khan J. Wu JT, et al. Among authors: wacheck v. Cancers (Basel). 2023 Aug 9;15(16):4034. doi: 10.3390/cancers15164034. Cancers (Basel). 2023. PMID: 37627061 Free PMC article.
Antisense molecules for targeted cancer therapy.
Wacheck V, Zangemeister-Wittke U. Wacheck V, et al. Crit Rev Oncol Hematol. 2006 Jul;59(1):65-73. doi: 10.1016/j.critrevonc.2005.10.004. Epub 2006 Jun 5. Crit Rev Oncol Hematol. 2006. PMID: 16750913 Review.
Short interfering RNA (siRNA): tool or therapeutic?
Cejka D, Losert D, Wacheck V. Cejka D, et al. Among authors: wacheck v. Clin Sci (Lond). 2006 Jan;110(1):47-58. doi: 10.1042/CS20050162. Clin Sci (Lond). 2006. PMID: 16336204 Review.
Incidence and Management of Olaratumab Infusion-Related Reactions.
Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Van Tine BA, et al. Among authors: wacheck v. J Oncol Pract. 2019 Nov;15(11):e925-e933. doi: 10.1200/JOP.18.00761. Epub 2019 Jul 3. J Oncol Pract. 2019. PMID: 31268811 Free PMC article.
81 results